- What: AstraZeneca provides funding and expertise through its long-term partnership with Tianjin University to build local manufacturing capacity.
- Objective: It aims to improve manufacturing safety standards at the industry level in China.
- Scope: The Tianjin University-AstraZeneca Joint Laboratory is not limited to a specific type of product or manufacturing process.
- Details: The partnership has been active since 2007 and is confirmed to run until at least 2017.
A researcher carries out crystallisation studies in automated multi-reactor equipment at Tianjin University and AstraZeneca’s shared lab facility.
AstraZeneca has a long-term partnership with Tianjin University that aims to improve manufacturing safety standards at the industry level in China. In 2006, AstraZeneca was seeking to expand its engagement with third-party manufacturers but identified widespread issues with manufacturing standards, especially safety, in China and the wider Asian region.
Given that the industry liaised with local universities to address manufacturing issues, the company partnered with Tianjin University Chemical Engineering School in northern China to address its concerns effectively and efficiently. Rather than training individual manufacturers, AstraZeneca provides funding, expertise (in the form of training, mentoring and coaching) and other support to the university’s Process Safety Laboratory to fill local skills gaps. The company’s expertise is shared with both students of the university (and is therefore an important source of skilled graduates entering the industry) and more widely via the university’s connections with manufacturers, to help improve manufacturing safety standards across the industry.
The partnership has been active since 2007 and is confirmed to run until at least 2017.
Many companies measured by the Access to Medicine Index build capacity of individual third-party manufacturers in countries in scope of the Index, with whom they have a direct relationship. It is unusual to build capacity at the industry level more broadly (i.e., including with manufacturers with whom AstraZeneca does not have a commercial relationship).